Indaptus Therapeutics (INDP) said Friday it sold about $2.3 million of convertible promissory notes and accompanying warrants in a private placement.
A health care-focused institutional investor led the transaction in an ongoing offering, in which Indaptus is looking to raise gross proceeds of up to $5 million, the company said.
Indaptus said the notes bear an annual interest rate of 6%, will mature on July 28, 2026 and will convert into common shares, while the warrants to purchase 200% of the conversion shares will be issued after the conversion of the notes and the receipt of stockholder approval.
The company said it plans to use the net proceeds for research and development, including a phase 1b/2 clinical trial, and for working capital and general corporate purposes.
Indaptus shares were 2.7% lower in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.